Evidence map›Paper›PMID 26189058›Full record

Trial reportJournal of neuro-oncology2015

Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.

Soléakhéna Ken, Alexandra Deviers, Thomas Filleron, Isabelle Catalaa, Jean-Albert Lotterie, Jonathan Khalifa, Vincent Lubrano, Isabelle Berry, Patrice Péran, Pierre Celsis and 2 more

Abstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Journal of neuro-oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Soléakhéna KenDepartment of Radiotherapy, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopôle, 1, avenue Irene Joliot-Curie, 31059, Toulouse, France. ken.soleakhena@iuct-oncopole.fr.
Alexandra DeviersDepartment of Radiotherapy, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopôle, 1, avenue Irene Joliot-Curie, 31059, Toulouse, France.
Thomas FilleronInstitut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopôle, Bureau des Essais Cliniques, 1, avenue Irene Joliot-Curie, 31059, Toulouse, France.
Isabelle CatalaaCentre Hospitalier Universitaire de Purpan, 31059, Toulouse, France.
Jean-Albert LotterieINSERM UMR 825 Imagerie Cérébrale et Handicaps Neurologiques, CHU Purpan - Pavillon Baudot, 31024, Toulouse, France.
Jonathan KhalifaDepartment of Radiotherapy, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopôle, 1, avenue Irene Joliot-Curie, 31059, Toulouse, France.
Vincent LubranoINSERM UMR 825 Imagerie Cérébrale et Handicaps Neurologiques, CHU Purpan - Pavillon Baudot, 31024, Toulouse, France.
Isabelle BerryINSERM UMR 825 Imagerie Cérébrale et Handicaps Neurologiques, CHU Purpan - Pavillon Baudot, 31024, Toulouse, France.
Patrice PéranINSERM UMR 825 Imagerie Cérébrale et Handicaps Neurologiques, CHU Purpan - Pavillon Baudot, 31024, Toulouse, France.
Pierre CelsisINSERM UMR 825 Imagerie Cérébrale et Handicaps Neurologiques, CHU Purpan - Pavillon Baudot, 31024, Toulouse, France.
Elizabeth Cohen-Jonathan MoyalDepartment of Radiotherapy, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopôle, 1, avenue Irene Joliot-Curie, 31059, Toulouse, France.
Anne LaprieDepartment of Radiotherapy, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopôle, 1, avenue Irene Joliot-Curie, 31059, Toulouse, France.
Inserm · FRCentre Hospitalier Universitaire de Toulouse · FRInstitut Claudius Regaud · FRUniversité Toulouse III - Paul Sabatier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously showed that the farnesyl transferase inihibitor, Tipifarnib induced vascularization normalization, oxygenation and radiosensitization in a pre-clinical glioblastoma (GBM) model. The aim of this study was to assess by dynamic-susceptibility-contrast MRI (DSC-MRI) the effect of radiotherapy (RT) and Tipifarnib combination on tumor perfusion in GBM patients. Eighteen patients with newly diagnosed GBM, enrolled in a phase I-II clinical trial associating RT with Tipifarnib, underwent anatomical MR imaging and DSC-MRI before (M0) and two months after treatment (M2). Anatomic volumes of interest (VOIs) were delineated according to contrast-enhanced and hyper-intense signal areas on T1-Gd and T2 images, respectively. Perfusion variations between M0 and M2 were assessed with median relative cerebral blood volume (rCBV) inside these VOIs. Another voxel by voxel analysis of CBV values classified 405,117 tumor voxels into High_, Normal_ and Low_CBVTUMOR according to the distribution of CBV in the contralateral normal tissue. These three categories of CBVTUMOR voxels were color-coded over anatomical MRI. Variations of median rCBV were significantly different for two groups of patients (P < 0.013): rCBV decreased when initial rCBV was ≥ 1.0 (Group_rCBV_M0 > 1) and rCBV increased when initial rCBV was < 1.0 (Group_rCBV_M0 < 1). Mapping of color-coded voxels provided additional spatial and quantitative information about tumor perfusion: Group_rCBV_M0 > 1 presented a significant decrease of High_CBVTUMOR volume (P = 0.015) simultaneously with a significant increase of Normal_CBVTUMOR volume (P = 0.009) after treatment. Group_rCBV_M0 < 1 presented a decrease of Low_CBVTUMOR volume with an increase of Normal_ and High_CBV TUMOR volume after treatment. Pre and post-treatment CBV measurements with DSC-MRI characterized tumor perfusion evolution in GBM patients treated with RT combined to Tipifarnib; showing variations in favour of tumor perfusion normalization in agreement with our pre-clinical results of vascular normalization.

Indexed as

AdultAgedAntineoplastic AgentsBrain NeoplasmsCerebrovascular CirculationContrast MediaFemaleFollow-Up StudiesGlioblastomaHumansImage Processing, Computer-AssistedMagnetic Resonance ImagingMaleMiddle AgedQuinolonesRadiotherapyAntineoplastic AgentsContrast MediaQuinolonestipifarnibAntiangiogenic therapyClinical TrialDynamic susceptibility-weighted contrast-enhanced MRIGlioblastomaRadiotherapyTumor Perfusion

Identifiers

PMID26189058
OpenAlexW1148420595

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.